Vir Biotechnology, Inc. (VIR)
| Market Cap | 1.67B +113.1% |
| Revenue (ttm) | 68.56M -7.6% |
| Net Income | -437.99M |
| EPS | -3.16 |
| Shares Out | 161.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,262,537 |
| Open | 10.59 |
| Previous Close | 10.35 |
| Day's Range | 10.00 - 10.64 |
| 52-Week Range | 4.16 - 11.66 |
| Beta | 1.66 |
| Analysts | Strong Buy |
| Price Target | 19.43 (+87.37%) |
| Earnings Date | May 6, 2026 |
About VIR
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting va... [Read more]
Financial Performance
In 2025, Vir Biotechnology's revenue was $68.56 million, a decrease of -7.61% compared to the previous year's $74.21 million. Losses were -$437.99 million, -16.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for VIR stock is "Strong Buy." The 12-month stock price target is $19.43, which is an increase of 87.37% from the latest price.
News
Vir Biotechnology to Host Conference Call for First Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, May 6 to provide a corporate upd...
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that its global collaboration and licensing agreement with Astellas announced on February 23, 2026 has closed foll...
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500, ...
Vir Biotechnology Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a robust immuno-oncology and infectious disease pipeline, highlighted by strong efficacy and safety data for its masked T-cell engager in prostate cancer and a promising dual regimen for hepatitis delta. Strategic partnerships and financing have extended cash runway to 2028.
Vir Biotechnology Transcript: TD Cowen 46th Annual Health Care Conference
VIR-5500 showed strong efficacy and safety in late-stage prostate cancer, enabling expansion and pivotal trials next year. The Astellas partnership accelerates development with significant financial terms and joint governance. Pipeline and HDV programs advance, with a robust cash position supporting growth.
Vir Biotechnology to Participate in Upcoming Investor Conferences
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of Mar...
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing...
Vir Biotechnology Announces Proposed Public Offering of Common Stock
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing...
These Analysts Boost Their Forecasts On Vir Biotechnology
Vir Biotechnology reported a fourth-quarter loss of 31 cents, beating the consensus loss of 41 cents. Sales reached $64.07 million, surpassing the consensus of $23.18 million.
What's Happening With VIR Stock?
Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer treatment, VIR-5500, along with encouraging P...
Vir Biotechnology Earnings Call Transcript: Q4 2025
Announced a $1.7B strategic collaboration with Astellas for VIR-5500, supported by strong phase I data showing deep and durable responses in late-line mCRPC. Financial discipline improved 2025 results, and the PRO-XTEN platform is validated for broader oncology applications.
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. “T...
Astellas collaborates with Vir to develop its experimental prostate cancer drug
Japan's Astellas and Vir Biotechnology said on Monday they will together develop and commercialize the U.S. drug developer's prostate cancer experimental drug.
Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targetin...
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechn...
Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will host a conference call at 5:30 p.m. ET / 2:30 p.m. PT on Monday, February 23 to provide a corporate u...
Vir Biotechnology Transcript: 44th Annual J.P. Morgan Healthcare Conference
The presentation detailed progress on a transformative pipeline targeting hepatitis Delta and solid tumors, with lead assets showing strong efficacy and safety. Strategic partnerships and a robust discovery engine support long-term growth, with key data readouts and commercial milestones expected through 2027.
Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided key program updates, including new positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta...
Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 44th Annual J.P. Morgan ...
Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty phar...
Vir Biotechnology Transcript: Evercore ISI 8th Annual HealthCONx Conference
Significant clinical progress was made with T cell engagers and hepatitis delta programs, including promising early efficacy and safety data. Dual-masked technology enables targeted activation and less frequent dosing. Upcoming data will further clarify efficacy, safety, and future positioning.
Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8...
Vir Biotechnology Transcript: Jefferies London Healthcare Conference 2025
Innovative dual-masking technology is driving progress in both oncology and infectious disease pipelines, with promising early clinical results and a strong financial position supporting advancement. Key catalysts include upcoming data for prostate cancer and hepatitis delta programs.
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company's Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonst...
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Hea...